tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Ocular Therapeutix Enters Quiet Period Ahead of SOL-1 Milestone
PremiumCompany AnnouncementsOcular Therapeutix Enters Quiet Period Ahead of SOL-1 Milestone
2M ago
Strong Buy Rating for Ocular Therapeutix Backed by Enhanced Regulatory Pathway and Promising Axpaxli Trial Data
Premium
Ratings
Strong Buy Rating for Ocular Therapeutix Backed by Enhanced Regulatory Pathway and Promising Axpaxli Trial Data
2M ago
Ocular Therapeutix price target raised to $21 from $18 at BofA
Premium
The Fly
Ocular Therapeutix price target raised to $21 from $18 at BofA
2M ago
Ocular announces plans to accelerate AXPAXLI NDA submission timeline
PremiumThe FlyOcular announces plans to accelerate AXPAXLI NDA submission timeline
2M ago
Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright
Premium
The Fly
Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright
2M ago
Strategic Early Approval Pathway for Ocular Therapeutix’s Axpaxli Bolsters Buy Rating
Premium
Ratings
Strategic Early Approval Pathway for Ocular Therapeutix’s Axpaxli Bolsters Buy Rating
2M ago
Ocular Therapeutix reports inducement grant under Nasdaq listing rule
PremiumThe FlyOcular Therapeutix reports inducement grant under Nasdaq listing rule
3M ago
Ocular Therapeutix Reports Q3 2025 Financial Results
Premium
Company Announcements
Ocular Therapeutix Reports Q3 2025 Financial Results
3M ago
Ocular Therapeutix Earnings Call: Optimism Amid Challenges
Premium
Company Announcements
Ocular Therapeutix Earnings Call: Optimism Amid Challenges
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100